Prognostic values of transketolase family genes in ovarian cancer

Zhao,Menghuang; Ye,Miaomiao; Zhou,Junhan; Zhu,Xueqiong

doi:10.3892/ol.2019.10818

Prognostic values of transketolase family genes in ovarian cancer

Authors:
- Menghuang Zhao
- Miaomiao Ye
- Junhan Zhou
- Xueqiong Zhu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China
Published online on: September 6, 2019 https://doi.org/10.3892/ol.2019.10818
Pages: 4845-4857
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transketolase genes are key rate‑limiting enzymes in the non‑oxidative part of the pentose phosphate pathway, which is an important metabolic pathway in ribose‑5‑phosphate production. Three human transketolase genes have been identified: Transketolase (TKT), transketolase‑like gene 1 (TKTL1) and transketolase‑like gene 2 (TKTL2). Transketolase genes serve crucial roles in the tumorigenesis, metastasis and outcome of multiple types of cancer. However, the expression levels and prognostic values of transketolase family genes in patients with ovarian cancer remain unclear. The purpose of the study was to analyze the expression level and prognostic significance of transketolase family genes in ovarian cancer. In the present study, the mRNA expression levels of three transketolase genes in ovarian cancer and normal ovarian tissue were compared by Oncomine. The prognostic values of these genes were systemically assessed using the Kaplan‑Meier plotter database. In addition, the associations between the mRNA levels of these transketolase genes and the clinicopathological characteristics of patients with ovarian cancer, such as histological subtype, clinical stage, grade, tumor protein p53 (TP53) mutation status and chemotherapy history were studied. The prognostic roles of transketolase genes were also evaluated in a validation dataset. The results demonstrated that TKT and TKTL1 expression in ovarian cancer tissues was elevated compared with that in normal ovarian tissues. In addition, high mRNA expression of the three transketolase genes was identified to be associated with poorer progression‑free survival (PFS) in patients with serous ovarian cancer, especially in patients at an advanced stage. TKTL2 was significantly associated with poor overall survival in all patients with ovarian cancer. Additionally, transketolase family genes served a role in predicting PFS in patients with ovarian cancer treated with platinum and/or taxol. High expression of the three transketolase genes was associated with unfavorable PFS in patients with TP53‑mutated ovarian cancer, but not in patients with TP53 wild‑type ovarian cancer. These results suggested that transketolase family genes may serve important roles in the prognosis of patients with ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, et al: Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet. 377:127–138. 2011. View Article : Google Scholar : PubMed/NCBI
3	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
4	Ward PS and Thompson CB: Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell. 21:297–308. 2012. View Article : Google Scholar : PubMed/NCBI
5	Zheng Y, Huang Q, Ding Z, Liu T, Xue C, Sang X and Gu J: Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma. Brief Bioinform. 19:101–108. 2018.PubMed/NCBI
6	Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A and Cascante M: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 6:e253232011. View Article : Google Scholar : PubMed/NCBI
7	Kowalik MA, Columbano A and Perra A: Emerging role of the pentose phosphate pathway in hepatocellular carcinoma. Front Oncol. 7:872017. View Article : Google Scholar : PubMed/NCBI
8	Jiang P, Du W and Wu M: Regulation of the pentose phosphate pathway in cancer. Protein Cell. 5:592–602. 2014. View Article : Google Scholar : PubMed/NCBI
9	Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS and Schirmer WJ: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 57:4242–4248. 1997.PubMed/NCBI
10	Coy JF, Dressler D, Wilde J and Schubert P: Mutations in the transketolase-like gene TKTL1: Clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab. 51:257–273. 2005.PubMed/NCBI
11	Zhao J and Zhong CJ: A review on research progress of transketolase. Neurosci Bull. 25:94–99. 2009. View Article : Google Scholar : PubMed/NCBI
12	Li J, Zhu SC, Li SG, Zhao Y, Xu JR and Song CY: TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 74:71–76. 2015. View Article : Google Scholar : PubMed/NCBI
13	Fritz P, Coy JF, Murdter TE, Ott G, Alscher MD and Friedel G: TKTL-1 expression in lung cancer. Pathol Res Pract. 208:203–209. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK and Califano JA: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 16:857–866. 2010. View Article : Google Scholar : PubMed/NCBI
15	Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Hausler SF, Dombrowski Y, Kapp M, Dietl J and Honig A: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 30:1653–1659. 2010.PubMed/NCBI
16	Chao YK, Peng TL, Chuang WY, Yeh CJ, Li YL, Lu YC and Cheng AJ: Transketolase serves a poor prognosticator in esophageal cancer by promoting cell Invasion via epithelial-mesenchymal transition. J Cancer. 7:1804–1811. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M and Zur Hausen A: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 43:719–724. 2011. View Article : Google Scholar : PubMed/NCBI
18	Song Y, Liu D and He G: TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 15:591–597. 2015. View Article : Google Scholar : PubMed/NCBI
19	Benito A, Polat IH, Noe V, Ciudad CJ, Marin S and Cascante M: Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget. 8:106693–106706. 2017. View Article : Google Scholar : PubMed/NCBI
20	Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 94:578–585. 2006. View Article : Google Scholar : PubMed/NCBI
21	Bery A, Leung F, Smith CR, Diamandis EP and Kulasingam V: Deciphering the ovarian cancer ascites fluid peptidome. Clin Proteomics. 11:132014. View Article : Google Scholar : PubMed/NCBI
22	Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P and Oehler MK: Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis. 32:441–455. 2015. View Article : Google Scholar : PubMed/NCBI
23	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
24	Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
25	Gyorffy B, Surowiak P, Budczies J and Lanczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
26	Gyorffy B, Lanczky A and Szallasi Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhao M, Li S, Zhou L, Shen Q, Zhu H and Zhu X: Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients. Life Sci. 194:34–39. 2018. View Article : Google Scholar : PubMed/NCBI
28	Tian X, Han Y, Yu L, Luo B, Hu Z, Li X, Yang Z, Wang X, Huang W, Wang H, et al: Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer. Cancer Biol Ther. 18:245–251. 2017. View Article : Google Scholar : PubMed/NCBI
29	Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
30	Tseng CW, Kuo WH, Chan SH, Chan HL, Chang KJ and Wang LH: Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the α-Ketoglutarate signaling pathway. Cancer Res. 78:2799–2812. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yang H, Wu XL, Wu KH, Zhang R, Ju LL, Ji Y, Zhang YW, Xue SL, Zhang YX, Yang YF and Yu MM: MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am J Cancer Res. 6:2690–2699. 2016.PubMed/NCBI
32	Chen Y, Xiong X, Wang Y, Zhao J, Shi H, Zhang H, Wang Y, Wei Y, Xue W and Zhang J: Proteomic screening for serum biomarkers for cervical cancer and their clinical significance. Med Sci Monit. 25:288–297. 2019. View Article : Google Scholar : PubMed/NCBI
33	Yi H, Zheng X, Song J, Shen R, Su Y and Lin D: Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: A proteomics analysis. Int J Clin Exp Pathol. 8:15719–15728. 2015.PubMed/NCBI
34	Zheng Y, Ming P, Zhu C, Si Y, Xu S, Chen A, Wang J and Zhang B: Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction. J Biol Chem. 294:4815–4827. 2019. View Article : Google Scholar : PubMed/NCBI
35	Lin CC, Chen LC, Tseng VS, Yan JJ, Lai WW, Su WP, Lin CH, Huang CY and Su WC: Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J. 37:1453–1465. 2011. View Article : Google Scholar : PubMed/NCBI
36	Ahopelto K, Bockelman C, Hagstrom J, Koskensalo S and Haglund C: Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol Ther. 17:163–168. 2016. View Article : Google Scholar : PubMed/NCBI
37	Shi Z, Tang Y, Li K and Fan Q: TKTL1 expression and its downregulation is implicated in cell proliferation inhibition and cell cycle arrest in esophageal squamous cell carcinoma. Tumour Biol. 36:8519–8529. 2015. View Article : Google Scholar : PubMed/NCBI
38	Schwaab J, Horisberger K, Ströbel P, Bohn B, Gencer D, Kähler G, Kienle P, Post S, Wenz F, Hofmann WK, et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer. 11:3632011. View Article : Google Scholar : PubMed/NCBI
39	Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J and Voelker HU: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: Activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 139:72–78. 2008. View Article : Google Scholar : PubMed/NCBI
40	Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kapp M, Horn E, Dietl J and Kammerer U: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer. 17:101–106. 2007. View Article : Google Scholar : PubMed/NCBI
41	Chen H, Yue JX, Yang SH, Ding H, Zhao RW and Zhang S: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 28:432009. View Article : Google Scholar : PubMed/NCBI
42	Zhang S, Yang JH and Cai PC: Effects of transketolase-like gene TKTL1 on occurrence and metastasis of human nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi. 88:3131–3134. 2008.(In Chinese). PubMed/NCBI
43	Ge L, Li N, Yuan GW, Sun YC and Wu LY: Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. Am J Cancer Res. 8:1074–1082. 2018.PubMed/NCBI
44	Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR and Hasan J: Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI
45	Taoka Y, Matsumoto K, Ohashi K, Minamida S, Hagiwara M, Nagi S, Saito T, Kodera Y and Iwamura M: Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis. Biomed Res. 36:253–261. 2015. View Article : Google Scholar : PubMed/NCBI
46	Zheng X and Li H: TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel. Biochem Biophys Res Commun. 503:572–579. 2018. View Article : Google Scholar : PubMed/NCBI
47	Na K, Sung JY and Kim HS: TP53 Mutation status of tubo-ovarian and peritoneal high-grade serous carcinoma with a wild-type p53 immunostaining pattern. Anticancer Res. 37:6697–6703. 2017.PubMed/NCBI
48	Kalamanathan S, Bates V, Lord R and Green JA: The mutational profile of sporadic epithelial ovarian carcinoma. Anticancer Res. 31:2661–2668. 2011.PubMed/NCBI
49	Munksgaard PS and Blaakaer J: The association between endometriosis and ovarian cancer: A review of histological, genetic and molecular alterations. Gynecol Oncol. 124:164–169. 2012. View Article : Google Scholar : PubMed/NCBI
50	Harami-Papp H, Pongor LS, Munkacsy G, Horvath G, Nagy AM, Ambrus A, Hauser P, Szabo A, Tretter L and Gyorffy B: TP53 mutation hits energy metabolism and increases glycolysis in breast cancer. Oncotarget. 7:67183–67195. 2016. View Article : Google Scholar : PubMed/NCBI